• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Edwards Lifesciences Corporation

    7/31/24 4:20:36 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email
    S-8 1 s-8ltsicp.htm S-8 Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ___________________

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    ___________________
     
    EDWARDS LIFESCIENCES CORPORATION
    (Exact name of registrant as specified in its charter)
    ___________________
    Delaware  36-4316614
    (State or other jurisdiction
    of incorporation or organization)
      (IRS Employer
    Identification No.)

    One Edwards Way
    Irvine, California 92614
    (Address, including zip code, of Principal Executive Offices)
    ___________________

    Edwards Lifesciences Corporation
    Long-Term Stock Incentive Compensation Program
    (Full title of the plan)
    ___________________

    Arnold A. Pinkston
    Corporate Vice President, General Counsel
    Edwards Lifesciences Corporation
    One Edwards Way
    Irvine, California 92614
    (949) 250-2500
    (Name, address and telephone number, including area code, of agent for service)

    ___________________
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer þ Accelerated filer o

    Non-accelerated filer o Smaller reporting company o

    Emerging growth company o

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o



    PART I

    INFORMATION REQUIRED IN THE
    SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).


    PART II

    INFORMATION REQUIRED IN THE
    REGISTRATION STATEMENT

    Item 3.        Incorporation of Certain Documents by Reference

    The following documents of Edwards Lifesciences Corporation (the “Company” or “Registrant”) filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:

    (a)The Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023, filed with the Commission on February 12, 2024 (Commission File No. 001-15525);

    (b)The portions of the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on March 26, 2024, that are incorporated by reference in Part III of the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023 (Commission File No. 001-15525);

    (c)The Company’s Quarterly Reports on Form 10-Q for its fiscal quarters ended March 31, 2024 and June 30, 2024, filed with the Commission on April 29, 2024 and July 31, 2024, respectively (each, Commission File No. 001-15525);

    (d)The Company’s Current Reports on Form 8-K, filed with the Commission on March 26, 2024, May 8, 2024, June 3, 2024, June 17, 2024, July 10, 2024, July 15, 2024, and July 24, 2024 (each, Commission File No. 001-15525 and in each case only as to the information “filed” with the Commission thereunder for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and not as to information “furnished” thereunder); and

    (e)The description of the Company’s Common Stock contained in Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Commission on February 13, 2023, which updated the description thereof contained in Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form 10, filed with the Commission on April 5, 2000 (each, Commission File No. 001-15525), and any other amendments or reports filed for the purpose of updating such description.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be
    2


    incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

    Item 4.        Description of Securities

    Not applicable.

    Item 5.        Interests of Named Experts and Counsel

    The validity of the issuance of Common Stock registered hereby is passed on for the Company by Linda J. Park. Ms. Park is the Company’s Senior Vice President, Associate General Counsel and Corporate Secretary and is compensated by the Company as an employee. Ms. Park has participated in and holds awards granted under the Company’s equity and long-term compensation plans, owns shares of Common Stock, and is eligible to participate in the Company’s Long-Term Stock Incentive Compensation Program.

    Item 6.        Indemnification of Directors and Officers

    Section 145(a) of the Delaware General Corporation Law (the “DGCL”) provides, in relevant part, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. Under Section 145(b) of the DGCL, such eligibility for indemnification may be further subject to the adjudication of the Delaware Court of Chancery or the court in which such action or suit was brought.

    Section 102(b)(7) of the DGCL provides that a corporation may, in its certificate of incorporation, eliminate or limit the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director except for liability: (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the DGCL (pertaining to certain prohibited acts including unlawful payment of dividends or unlawful purchase or redemption of the corporation’s capital stock); or (iv) for any transaction from which the director derived an improper personal benefit. The Company’s certificate of incorporation eliminates such personal liability of the Company’s directors under such terms.

    The Company’s certificate of incorporation requires the Company to provide indemnification to each person who serves as an officer or director, and each person who serves or may have served at the Company’s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, from any liability incurred as a result of such service to the fullest extent permitted by the DGCL, and the Company may advance such person’s related expenses, to the fullest extent permitted by the DGCL. In addition, the Company has entered into indemnification agreements with each of the Company’s directors and executive officers, and the Company maintains directors’ and officers’ liability insurance under which the Company’s directors and officers are insured against loss (as defined in the policy) as a result of certain claims brought against them in such capacities.

    Item 7.        Exemption from Registration Claimed

    Not applicable.

    3


    Item 8.        Exhibits

    See the attached Exhibit Index at page 5, which is incorporated herein by reference.

    Item 9.        Undertakings

    (a)The undersigned Registrant hereby undertakes:

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement;

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (h)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 above, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    4


    EXHIBIT INDEX

    Exhibit NumberDescription of Exhibit
    4
    Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program
    5
    Opinion of Counsel (opinion re legality)
    23.1
    Consent of PricewaterhouseCoopers LLP (consent of independent registered public accounting firm)
    23.2
    Consent of Counsel (included in Exhibit 5)
    24
    Power of Attorney (included in this Registration Statement under “Signatures”)
    107
    Filing Fee Table



    5


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on July 31, 2024.


    EDWARDS LIFESCIENCES CORPORATION
    By:/s/ Linda J. Park
    Linda J. Park
    Senior Vice President, Associate General Counsel, and Corporate Secretary






    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Scott B. Ullem, Arnold A. Pinkston, and Linda J. Park, and each of them, acting individually and without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.


    SignatureTitleDate
    /s/ Bernard J. Zovighian
    Bernard J. Zovighian
    Chief Executive Officer and Director
    (Principal Executive Officer)
    July 31, 2024
    /s/ Scott B. Ullem
    Scott B. Ullem
    Corporate Vice President and Chief Financial Officer
    (Principal Financial Officer)
    July 31, 2024
    6


    /s/ Andrew M. Dahl
    Andrew M. Dahl
    Senior Vice President, Corporate Controller and Principal Accounting Officer
    (Principal Accounting Officer)
    July 31, 2024
    /s/ Nicholas J. Valeriani
    Nicholas J. Valeriani
    Chairman of the BoardJuly 31, 2024
    /s/ Leslie C. Davis
    Leslie C. Davis
    DirectorJuly 31, 2024
    /s/ David T. Feinberg
    David T. FeinbergDirectorJuly 31, 2024
    /s/ Kieran T. Gallahue
    Kieran T. GallahueDirectorJuly 31, 2024
    /s/ Leslie S. Heisz
    Leslie S. HeiszDirectorJuly 31, 2024
    /s/ Paul A. LaViolette
    Paul A. LaVioletteDirectorJuly 31, 2024
    /s/ Steven R. Loranger
    Steven R. LorangerDirectorJuly 31, 2024
    /s/ Ramona Sequeira
    Ramona SequeiraDirectorJuly 31, 2024
    7
    Get the next $EW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    1/9/2026$97.00Hold → Buy
    TD Cowen
    12/18/2025$100.00Neutral → Overweight
    Analyst
    11/3/2025$96.00Mkt Perform → Outperform
    Raymond James
    10/29/2025Underperform → Peer Perform
    Wolfe Research
    10/29/2025$98.00Hold → Buy
    Jefferies
    10/8/2025Outperform → Perform
    Oppenheimer
    10/7/2025$88.00In-line → Outperform
    Evercore ISI
    7/29/2025$100.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $EW
    SEC Filings

    View All

    Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    2/10/26 4:22:48 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    1/9/26 6:51:56 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Edwards Lifesciences Corporation

    10-Q - Edwards Lifesciences Corp (0001099800) (Filer)

    11/5/25 4:12:51 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences

    Edwards Lifesciences Corporation (NYSE:EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026 at 10:00 a.m. ET at the Barclays 28th Annual Global Healthcare Conference Wednesday, March 11, 2026 at 10:00 a.m. ET at the Leerink Global Healthcare Conference A live webcast of each presentation will be available on the Edwards investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakth

    2/19/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Present at Citi's 2026 Unplugged Medtech and Life Sciences Access Day

    Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial officer, is scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeho

    2/13/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports Fourth Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

    2/10/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    5/7/24 5:53:27 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CVP, TAVR Lippis Daniel J. was granted 12,820 shares and covered exercise/tax liability with 456 shares, increasing direct ownership by 56% to 34,366 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/17/26 5:16:02 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, Chief Financial Officer Ullem Scott B. covered exercise/tax liability with 199 shares, decreasing direct ownership by 0.50% to 39,699 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/17/26 5:16:03 PM ET
    $EW
    Industrial Specialties
    Health Care

    CEO Zovighian Bernard J sold $1,719,741 worth of shares (22,430 units at $76.67), gifted 2,920 shares, received a gift of 2,920 shares and exercised 25,350 shares at a strike of $59.26 (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/13/26 5:37:29 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Edwards Lifesciences upgraded by TD Cowen with a new price target

    TD Cowen upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $97.00

    1/9/26 8:27:58 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Analyst with a new price target

    Analyst upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $100.00

    12/18/25 8:41:18 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Raymond James with a new price target

    Raymond James upgraded Edwards Lifesciences from Mkt Perform to Outperform and set a new price target of $96.00

    11/3/25 9:08:28 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    View All

    Edwards Lifesciences Announces CFO Transition Plan

    Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp

    10/30/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

    SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE:EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most suc

    8/25/25 4:33:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

    Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

    3/6/25 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Financials

    Live finance-specific insights

    View All

    Edwards Lifesciences Reports Fourth Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

    2/10/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians an

    2/3/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference

    Innovation with Purpose, Powered by Science, Centered on Patients: Edwards' Commitment to Drive Value for the Healthcare Ecosystem Edwards Lifesciences (NYSE:EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunities to advance treatments for aortic regurgitation (AR) and structural heart failure. "As we enter 202

    12/4/25 9:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Edwards Lifesciences Corporation

    SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

    11/8/24 10:34:33 AM ET
    $EW
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    10/4/24 2:14:28 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    2/13/24 5:04:42 PM ET
    $EW
    Industrial Specialties
    Health Care